Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Refana","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panacea Biotech to Partner with US Firm Refana for COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panacea Biotec Aims to Make 1 Billion Doses of COVID-19 Vaccine Candidate in 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panacea Biotec Successfully completes Phase I\/II Study of Its Novel, Tetravalent Recombinant Chimeric Dengue Candidate Vaccine, DengiAll","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Nuvation Bio","pharmaFlowCategory":"D","amount":"$830.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panacea Biotec Announces Successful Completion Of Phase I\/II Study of Its Novel, Tetravalent Recombinant Chimeric Dengue Candidate Vaccine, DengiAll","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","amount":"$251.1 million","upfrontCash":"Undisclosed","newsHeadline":"Panacea Biotec Sells Domestic Formulation Assets To Mankind Pharma for Rs 1,908 Crore","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panacea Biotec Launches EasyFourPol in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Vaccine","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Panacea Biotec Limited

    Menu

    Panacea Biotec Limited

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Panacea Biotec Limited

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Panacea Biotec Launches EasyFourPol in India

              Details:

              EasyFourPol is the world's first fully-liquid wP-IPV based Pentavalent vaccine, which is launched in India to protect children against five deadly diseases: Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b.

              Lead Product(s): Hib DTP Poliovirus Vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: EasyFourPol

              Highest Development Status: Approved Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Panacea Biotec Limited

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Panacea Biotec Sells Domestic Formulation Assets To Mankind Pharma for Rs 1,908 Crore

              Details:

              The top selling brands are Pangraf (tacrolimus), Alphadol (alfacalcidol), Cilamin (penicillamine) & Livoluk Fibre (lactulose in combination with ispaghula) were ranked number 1, whereas Glizid (Gliclazide + Metformin), Mycept (Mycophenolate Mofetil) were among the top 5.

              Lead Product(s): Tacrolimus

              Therapeutic Area: Dermatology Product Name: Pangraf

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Mankind Pharma

              Deal Size: $251.1 million Upfront Cash: Undisclosed

              Deal Type: Agreement February 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Panacea Biotec Limited

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Panacea Biotec Announces Successful Completion Of Phase I/II Study of Its Novel, Tetravalent Recombinant Chimeric Dengue Candidate Vaccine, DengiAll

              Details:

              DengiAll, a single-dose live-attenuated tetravalent vaccine induced robust, balanced neutralizing antibody responses against all four Dengue virus serotypes. After single-dose, more than 80% of participants showed Tri-valent response and ~95% showed multivalent response.

              Lead Product(s): Tetravalent Recombinant Chimeric Dengue Vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: DengiAll

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Panacea Biotec Limited

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company

              Details:

              Patient recruitment and dosing is ongoing in Nuvation Bio’s Phase 1/2 study of its lead investigational compound, NUV-422, a CDK2/4/6 inhibitor, in patients with high-grade gliomas, including glioblastoma multiforme (GBM).

              Lead Product(s): NUV-422

              Therapeutic Area: Oncology Product Name: NUV-422

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Recipient: Nuvation Bio

              Deal Size: $830.0 million Upfront Cash: Undisclosed

              Deal Type: Merger February 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Panacea Biotec Limited

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Panacea Biotec Successfully completes Phase I/II Study of Its Novel, Tetravalent Recombinant Chimeric Dengue Candidate Vaccine, DengiAll

              Details:

              DengiAll has illustrated the strength of Panacea Biotec’s expertise in vaccinology, research, development, and manufacturing while leveraging NIH’s ability to work on complex biological challenges to develop breakthrough technologies.

              Lead Product(s): Tetravalent recombinant chimeric Dengue vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: DengiAll

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Panacea Biotec Limited

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Panacea Biotec Aims to Make 1 Billion Doses of COVID-19 Vaccine Candidate in 2022

              Details:

              Panacea Biotec has set production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate.

              Lead Product(s): Covid-19 vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Panacea Biotec Limited

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Panacea Biotech to Partner with US Firm Refana for COVID-19 vaccine

              Details:

              Under the collaboration, Panacea Biotec will be responsible for product development and commercial manufacturing, with the Joint Venture undertaking clinical development and regulatory submissions across the World.

              Lead Product(s): Covid-19 vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Refana

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 10, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY